Abstracts tagged "Psoriatic arthritis"

Abstract Number: 930 • 2016 ACR/ARHP Annual Meeting
How to Implement Cardiovascular Disease Risk Assessment for Patients with Inflammatory Joint Diseases in Daily Rheumatology Practice: An Overview of a Nationwide Norwegian Project
Eirik Ikdahl¹, Silvia Rollefstad², Grunde Wibetoe³, Anne Salberg⁴, Dag Magnar Soldal⁵, Inge C Olsen⁶, Tore K Kvien⁶, Glenn Haugeberg⁷ and Anne Grete Semb¹, ¹Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁵Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, ⁶Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁷Martina Hansens Hospital, Bærum, Norway
Background/Purpose: The EULAR recommendations for cardiovascular disease (CVD) risk management in patients with inflammatory joint diseases (IJD) states that CVD risk assessment should be considered…
Abstract Number: 1713 • 2016 ACR/ARHP Annual Meeting
Long-Term (156-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of 3 Phase III, Randomized, Controlled Trials
Philip J Mease¹, Dafna D Gladman², Juan J Gomez-Reino³, Stephen Hall⁴, Arthur Kavanaugh⁵, Eric Lespessailles⁶, Georg Schett⁷, Kamal Shah⁸, Lichen Teng⁸ and Jürgen Wollenhaupt⁹, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Toronto Western Research Institute, Toronto, ON, Canada, ³Hospital Clinico Universitario, Santiago, Spain, ⁴Monash University, CabriniHealth, Melbourne, Australia, ⁵University of California, San Diego, School of Medicine, La Jolla, CA, ⁶University of Orléans, Orléans, France, ⁷University of Erlangen-Nuremberg, Erlangen, Germany, ⁸Celgene Corporation, Summit, NJ, ⁹Schön Klinik Hamburg-Eilbek, Hamburg, Germany
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, acts to regulate immune activity in psoriatic arthritis (PsA) patients. PALACE 1 (NCT01172938), 2 (NCT01212757), and 3…
Abstract Number: 3085 • 2016 ACR/ARHP Annual Meeting
Do Depression and Anxiety Reduce the Chance of Remission in Rheumatoid Arthritis and Psoriatic Arthritis?
Brigitte Michelsen^1,2, Karen M Fagerli¹, Elisabeth Lie¹, Hilde Berner Hammer³, Glenn Haugeberg^4,5, Eirik K Kristianslund¹ and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept. of Rheumatology, Martina Hansens Hospital, Bærum, Norway, ⁵Dept. of Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway
Background/Purpose: Depression and anxiety are reported to predict poorer treatment outcomes in rheumatoid arthritis (RA).1 Whether this can be confirmed in larger, prospective studies as…
Abstract Number: 938 • 2016 ACR/ARHP Annual Meeting
Prevalence of Non-Radiographic Axial Spondyloarthritis in Psoriatic Arthritis – a Single Center Observational Study
Victoria Furer¹, Moshe Stark², Hagit Matz³, David Levartovsky⁴, Jonathan Wallman⁵, Irena Wigler⁶, Hagit Sarvagyl-Maman⁷, Ofir Elalouf⁸, Sara Borok Lev-Ran⁹, Daphna Paran⁶, Gideon Flusser¹⁰, Iddo Drukman¹⁰, Iris Eshed¹¹ and Ori Elkayam¹², ¹Rheumatology, Tel Aviv Sourasky Medical Center, The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ²Tel Aviv Medical Center, Tel Aviv, Tel Aviv, Israel, ³Dermatology, Tel Aviv Medical Center, Tel Aviv, Israel, ⁴Rheumatology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ⁵Rheumatology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel, ⁶Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁷Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel-aviv, Israel, ⁸Rheumatology, Tel Aviv Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel, ⁹Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine,Tel Aviv University, Tel AViv, Israel, ¹⁰Radiology, Tel Aviv Medical Center, Tel Aviv, Israel, ¹¹Department of Radiology, Sheba Medical Center, Israel, Tel Hashomer, Israel, ¹²Rheumatology, Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: Sacroiliitis, as detected by plain radiographs of the sacroiliac joints (SIJ), has been reported in a third of the psoriatic arthritis (PsA) population. (1)…
Abstract Number: 1722 • 2016 ACR/ARHP Annual Meeting
Predictors of Achieving Remission Among Patients with Psoriatic Arthritis Prescribed TNF Inhibitors
Alexis Ogdie¹, J. Lynn Palmer², Jeffrey D. Greenberg³, Leslie R. Harrold⁴, Daniel H. Solomon⁵, Arthur Kavanaugh⁶, Joel Kremer⁷, Philip J Mease⁸ and Jeffrey R. Curtis⁹, ¹Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ²Corrona Research Foundation, Albany, NY, ³New York University School of Medicine, New York, NY, ⁴University of Massachusetts Medical School, Worcester, MA, ⁵Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶University of California San Diego, La Jolla, CA, ⁷The Center for Rheumatology, Albany Medical College, Albany, NY, ⁸Rheumatology and Internal Medicine, Swedish Medical Center and University of Washington, Seattle, WA, ⁹Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease with varied response to therapy. We examined predictors of remission at one year among patients with PsA…
Abstract Number: 961 • 2016 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis through 3 Years: Efficacy and Safety Results from a Phase 3 Trial
Philip J Mease¹, Arthur Kavanaugh², Andreas Reimold³, Hasan Tahir⁴, Juergen Rech⁵, Stephen Hall⁶, Piet Geusens^7,8, Pellet Pascale⁹, Evie Maria Delicha¹⁰, Luminita Pricop¹¹ and Shephard Mpofu¹⁰, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²UC San Diego School of Medicine, La Jolla, CA, ³Dallas VA Medical Center and University of Texas Southwestern Medical Center, Dallas, TX, ⁴Barts Health NHS Trust, London, United Kingdom, ⁵Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁶Monash University, Melbourne, Australia, ⁷University of Hasselt, Hasselt, Belgium, ⁸Maastricht University Hospital, Maastricht, Netherlands, ⁹Novartis Pharma AG, basel, Switzerland, ¹⁰Novartis Pharma AG, Basel, Switzerland, ¹¹Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Secukinumab, an anti–interleukin-17A monoclonal antibody, provided rapid and significant improvements in the key clinical domains of psoriatic arthritis (PsA) in the FUTURE 1 study…
Abstract Number: 1728 • 2016 ACR/ARHP Annual Meeting
Comparison of Adherence to Disease Modifying Antirheumatic Drugs in Psoriatic Arthritis and Other Rheumatic Disease
Mehmet Ali Balci¹, Mustafa Ferhat Oksuz², Salim Donmez¹, Tugce Ozen³, Ediz Dalkilic², Ayse Nur Tufan², Yavuz Pehlivan² and Omer Nuri Pamuk⁴, ¹Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, ²Rheumatology, Uludag University Medcal Faculty, Bursa, Turkey, ³PHYSICAL THERAPY AND REHABILITATION, Trakya University Faculty of Health Sciences, Edirne, Turkey, ⁴Rheumatology, Department of Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, Edirne, Turkey
Background/Purpose: Psoriatic arthritis (PsA), Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are an inflammatory arthritis causing joint damage and disability. Non-adherence to disease modifying anti-rheumatic…
Abstract Number: 665 • 2015 ACR/ARHP Annual Meeting
Construct Validity of Disease Activity for Psoriatic Arthritis Composite Index and Tentative Cut-Off Values in a Cohort of Patients with Psoriatic Arthritis
Josefina Gallino Yanzi¹, Emilce Schneeberger¹, Osvaldo Luis Cerda¹, Cecilia Zaffarana¹, Margarita Landi¹, Marcos G. Rosemffet², Natalia Zamora³, Tomas Cazenave², Fernando Dal Pra¹, Paula Kohan⁴, Emilio Buschiazzo⁵ and Gustavo Citera², ¹Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁴Hospital Dr. E. Tornu, Buenos Aires, Argentina, ⁵Rheumatology, Hospital Sr Del Milagro, Salta, Argentina
Background/Purpose: Disease Activity for Psoriatic Arthritis (DAPSA) is a composite index that assesses disease activity in patients with Psoriatic Arthritis (PsA) taking into account peripheral…
Abstract Number: 2864 • 2015 ACR/ARHP Annual Meeting
Long-Term Work Productivity Improvement Associated with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Analysis of 3 Phase 3 Studies
Frank Zhang¹, Zoe Clancy² and Stan Li³, ¹Pricing and Market Access, I&I, Celgene Corporation, Warren, NJ, ²33 Technology Drive, Celgene Corporation, Warren, NJ, ³Celgene Corporation, Warren, NJ
Background/Purpose: Studies have shown that patients with psoriatic arthritis (PsA) have significantly compromised physical health and quality of life, and negative effect on work productivity…
Abstract Number: 667 • 2015 ACR/ARHP Annual Meeting
Comparison of Patient and Provider Assessments of Response to Therapy for Psoriatic Arthritis
Tobee Gunter¹ and Jessica Walsh², ¹Rheumatology, School of Medicine, University of Utah Internal Medicine, Salt Lake City, UT, ²Division of Rheumatology, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT
Background/Purpose: Little is known about how psoriatic arthritis patients and their providers perceive response to therapy. Discrepancies in perceptions of therapy response may indicate that…
Abstract Number: 2873 • 2015 ACR/ARHP Annual Meeting
Pharmacological Treatment of Psoriatic Arthritis (PSA): Systematic Literature Review for the Update of the EULAR Recommendations for the Management of PSA
Sofia Ramiro¹, Josef S. Smolen², Robert B.M. Landewé³, Désirée van der Heijde¹, Maxime Dougados⁴, Paul Emery⁵, Maarten de Wit⁶, Maurizio Cutolo⁷, Susan Oliver⁸ and Laure Gossec⁹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴Rheumatology Department, Cochin hospital, Paris-Descartes University, Paris, France, ⁵Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom, ⁶EULAR Social Leagues, Zurich, Switzerland, ⁷Division of Clinical Immunology, Dept Internal Medicine, University of Genova, Genova, Italy, ⁸Independent Nurse Consultant, North Devon, United Kingdom, ⁹Rheumatology, Pitié Salpetriere Hospital, Paris, France
Background/Purpose: As part of the update of the EULAR recommendations for the management of PsA, we performed a systematic literature review to assess the efficacy…
Abstract Number: 670 • 2015 ACR/ARHP Annual Meeting
Evaluation of the Predictive Value of Non-Specific Musculoskeletal Symptoms in Preclinical Phases of Psoriatic Arthritis
Lihi Eder¹, Ari Polachek¹, Cheryl Rosen², Vinod Chandran¹, Richard J. Cook³ and Dafna D. Gladman¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Dermatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: Limited information exists about the characteristics of pre-clinical phases of psoriatic arthritis (PsA). We aimed to assess whether the presence and trends in non-specific…
Abstract Number: 2874 • 2015 ACR/ARHP Annual Meeting
Two-Years Survival of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis and Predictors Thereof in Real-Life Settings
Leonardo Santo¹, Angelo Semeraro², Carmelo Zuccaro³, Maria Grazia Anelli⁴, Romano Bucci⁵, Antonio Marsico⁶, Laura Quarta⁷, Giorgio Carlino⁸, Francesco Paolo Cantatore⁹, Annamaria Gaudio¹⁰, Fabio Cacciapaglia¹¹, Oriana Casilli¹², Paola Chiara Francesca Falappone¹³ and Florenzo Iannone¹⁴, ¹DSS4 Barletta, ASL BT Andria - Rheumatology Service, Barletta, Italy, ²Unità Operativa di Reumatologia ASL Taranto, Taranto, Italy, ³U.O.of Geriatrics, Outpatient clinic of Rheumatology, Brindisi, Italy, ⁴DIM, Rheumatology Unit, Bari, Italy, ⁵A.O.U., Rheumatology Hospital Unit, Foggia, Italy, ⁶Outpatient clinic of Rheumatology, Taranto,, Italy, ⁷Department of Rheumatology, "V.Fazzi" Hospital, San Cesario di Lecce, Italy, ⁸ASL LE - DSS Casarano and Gallipoli, Rheumatology Service, Gallipoli, Italy, ⁹Department of Rheumatology, University of Foggia,, Foggia, Italy, ¹⁰Department of Rheumatology, University of Foggia, Foggia, Italy, ¹¹Internal Medicine Unit and Outpatient clinic of Rheumatology, “N. Melli” Hospital, San Pietro Vernotico (BR), Italy, ¹²Department of Rheumatology, "Vito Fazzi" Hospital, San Cesario di Lecce, Italy, ¹³Internal Medicine Unit - Outpatient clinic of Rheumatology,, "S. Camillo de' Lellis" Hospital, Mesagne (BR), Italy, ¹⁴Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy
Background/Purpose: It has previously been shown that the survival of anti-TNF drugs was lower in Rheumatoid arthritis (RA) than in other chronic arthritis1. The objective…
Abstract Number: 675 • 2015 ACR/ARHP Annual Meeting
Vitamin D Deficiency in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis. Results of the CARMA Study
Ana Urruticoechea¹, Maria Auxiliadora Martin², Santos Castañeda³, Carlos Alberto Sánchez-Piedra², Carlos González-Juanatey⁴, Javier Llorca⁵, Federico Díaz-González⁶ and Miguel Angel Gonzalez-Gay⁷, ¹Hospital Can Misses, Ibiza, Spain, ²Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, ³Rheumatology, H.U. La Princesa, Madrid, Spain, ⁴Division or Cardiology, Hospital Lusus Augusti, Lugo, Spain, ⁵Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ⁶Investigation Unit, Sociedad Española de Reumatológía, Madrid, Spain, ⁷Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: To study the association between 25-hydroxyvitamin D (25(OH)D) levels and the clinical characteristics of patients with chronic inflammatory rheumatic diseases (CIRD). Methods: Cross section…
Abstract Number: 2888 • 2015 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III, Randomized, Controlled Trials
Dafna D. Gladman¹, Arthur Kavanaugh², Adewale O. Adebajo³, Juan J. Gomez-Reino⁴, Jürgen Wollenhaupt⁵, Maurizio Cutolo⁶, Georg A. Schett⁷, Eric Lespessailles⁸, Melissa McIlraith⁹, ChiaChi Hu⁹, Christopher J. Edwards¹⁰, Charles A. Birbara¹¹ and Philip J. Mease¹², ¹Toronto Western Hospital, Toronto, ON, Canada, ²University of California, San Diego School of Medicine, LaJolla, CA, ³University of Sheffield, Sheffield, United Kingdom, ⁴Hospital Clinico Universitario, Santiago, Spain, ⁵Schön Klinik Hamburg Eilbek, Hamburg, Germany, ⁶University of Genova, Genova, Italy, ⁷University of Erlangen-Nuremberg, Erlangen, Germany, ⁸University of Orléans, Orléans, France, ⁹Celgene Corporation, Warren, NJ, ¹⁰University Hospital Southampton, Southampton, United Kingdom, ¹¹University of Massachusetts Medical School, Worcester, MA, ¹²Rheumatology Research, Swedish Medical Center, Seattle, WA
Background/Purpose: Apremilast (APR), a PDE4 inhibitor, helps regulate immune responses in psoriatic arthritis (PsA). PALACE 1, 2, and 3 compared apremilast (APR) efficacy/safety with placebo…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].